POSTER PRESENTATION AT WORLDSYMPOSIUM™ 2018 – ARIMOCLOMOL AS CLINICAL CANDIDATE FOR TREATMENT OF GAUCHER DISEASE

Copenhagen, February 6, 2018 – Orphazyme A/S, a Danish biotech company listed on Nasdaq Copenhagen (TICKER: ORPHA.CO), with a late-stage, orphan-drug pipeline, today announced that a poster on arimoclomol as a clinical candidate for the treatment of neuronopathic Gaucher disease will be presented at WORLDSymposium™ 2018 in San Diego, CA, USA.

The data, which will be presented today at 4.30 PM PST by Orphazyme’s Chief Scientific Officer, Thomas Kirkegaard Jensen, highlights the mechanism of action and efficacy of arimoclomol in preclinical models of Gaucher disease. A Phase II clinical trial of arimoclomol in Gaucher disease is planned to commence in Q2 2018.

There are currently no treatments available for the neurological symptoms of Gaucher disease. 

For an abstract of the poster, please follow this link: https://www.sciencedirect.com/science/article/pii/S1096719217309757.